Patents by Inventor Tetsuya Sekiguchi
Tetsuya Sekiguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240105826Abstract: A semiconductor device of an embodiment includes a semiconductor layer, a first insulating film provided on the semiconductor layer, a first electrode film provided on the first insulating film, a second electrode film provided on the first electrode film, and a first field plate electrode provided on the second electrode film. A lower end of the first field plate electrode is located on a second surface of the first electrode film, the second surface being in contact with the second electrode film, rather than a first surface of the first electrode film, the first surface being in contact with the first insulating film.Type: ApplicationFiled: March 1, 2023Publication date: March 28, 2024Inventors: Hitoshi KOBAYASHI, Masaaki ONOMURA, Toru SUGIYAMA, Akira YOSHIOKA, Hung HUNG, Hideki SEKIGUCHI, Tetsuya OHNO, Yasuhiro ISOBE
-
Publication number: 20240105563Abstract: A semiconductor device includes a nitride semiconductor element, a first diode, and a second diode; the nitride semiconductor element includes a conductive mounting bed, a semiconductor substrate formed on the mounting bed, a first nitride semiconductor layer, a second nitride semiconductor layer, a first major electrode, a second major electrode, a first gate electrode, and a second gate electrode; the first diode includes a first anode electrode electrically connected to the mounting bed, and a first cathode electrode electrically connected to the first major electrode; and the second diode includes a second anode electrode electrically connected to the mounting bed, and a second cathode electrode electrically connected to the second major electrode.Type: ApplicationFiled: March 9, 2023Publication date: March 28, 2024Inventors: Toru SUGIYAMA, Akira YOSHIOKA, Hitoshi KOBAYASHI, Hung HUNG, Yasuhiro ISOBE, Hideki SEKIGUCHI, Tetsuya OHNO, Masaaki ONOMURA
-
Publication number: 20240097671Abstract: A semiconductor device includes a first transistor, a first drive circuit including a second transistor, and a second drive circuit including a third transistor. The second transistor and the third transistor are connected in series; and a connection node of the second and third transistors is connected to a gate electrode of the first transistor. The first transistor, the second transistor, and the third transistor are normally-off MOS HEMTs formed in a first substrate that includes GaN. The first drive circuit charges a parasitic capacitance of the first transistor. The second drive circuit discharges the parasitic capacitance of the first transistor.Type: ApplicationFiled: February 10, 2023Publication date: March 21, 2024Inventors: Toru SUGIYAMA, Noriaki YOSHIKAWA, Yasuhiko KURIYAMA, Akira YOSHIOKA, Hitoshi KOBAYASHI, Hung HUNG, Yasuhiro ISOBE, Tetsuya OHNO, Hideki SEKIGUCHI, Masaaki ONOMURA
-
Publication number: 20240078831Abstract: To determine the state of a subject person with a simple structure, an image determining device includes: an imaging unit that captures an image from a first direction, the image including the subject person; a first detector that detects size information from the image, the size information being about the subject person in the first direction; a second detector that detects position-related information, the position-related information being different from the information detected by the first detector; and a determining unit that determines the state of the subject person, based on a result of the detection performed by the first detector and a result of the detection performed by the second detector.Type: ApplicationFiled: November 9, 2023Publication date: March 7, 2024Applicant: NIKON CORPORATIONInventors: Tetsuya YAMAMOTO, Masahiro NEI, Isao TOTSUKA, Tomoyuki MATSUYAMA, Masamitsu YANAGIHARA, Satoshi HAGIWARA, Masakazu SEKIGUCHI
-
Patent number: 10835520Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: GrantFiled: October 1, 2018Date of Patent: November 17, 2020Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Patent number: 10214540Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: GrantFiled: February 27, 2018Date of Patent: February 26, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Tatsuya Komagata, Takuya Nishio
-
Publication number: 20190030010Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: ApplicationFiled: October 1, 2018Publication date: January 31, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi NAGANAWA, Kensuke KUSUMI, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Akito KAKUUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Shigeyuki NONAKA
-
Patent number: 10117861Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: GrantFiled: October 16, 2017Date of Patent: November 6, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Publication number: 20180194775Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: ApplicationFiled: February 27, 2018Publication date: July 12, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu ISHIDA, Takeshi MATSUSHITA, Tetsuya SEKIGUCHI, Tatsuya KOMAGATA, Takuya NISHIO
-
Patent number: 9975904Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: GrantFiled: March 16, 2017Date of Patent: May 22, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Tatsuya Komagata, Takuya Nishio
-
Publication number: 20180042908Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: ApplicationFiled: October 16, 2017Publication date: February 15, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi NAGANAWA, Kensuke KUSUMI, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Akito KAKUUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Shigeyuki NONAKA
-
Patent number: 9820980Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: GrantFiled: April 4, 2016Date of Patent: November 21, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Publication number: 20170183359Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: ApplicationFiled: March 16, 2017Publication date: June 29, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu ISHIDA, Takeshi MATSUSHITA, Tetsuya SEKIGUCHI, Tatsuya KOMAGATA, Takuya NISHIO
-
Patent number: 9676719Abstract: An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.Type: GrantFiled: March 25, 2014Date of Patent: June 13, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Kensuke Kusumi, Atsushi Naganawa, Kazuhiro Otsuki, Tetsuya Sekiguchi, Koji Shinozaki, Hiroshi Yamamoto, Yasuko Yamamoto
-
Patent number: 9643951Abstract: The present invention provides a somatostatin receptor subtype 2 agonist. A disclosed compound represented by the general formula (I): wherein all symbols have the same definitions as described in the specification; a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing is a low-molecular compound having strong somatostatin receptor subtype 2 agonistic activity, and thus can be administered in a simple manner, has high stability and has low toxicity. Therefore, the present compound is useful for prophylaxis and/or therapy of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.Type: GrantFiled: September 29, 2014Date of Patent: May 9, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Yasuyuki Okabe, Tatsuya Komagata, Takuya Nishio
-
Patent number: 9630976Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): [wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.Type: GrantFiled: July 2, 2013Date of Patent: April 25, 2017Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu Ishida, Takeshi Matsushita, Tetsuya Sekiguchi, Tatsuya Komagata, Takuya Nishio
-
Publication number: 20160311794Abstract: The present invention provides a somatostatin receptor subtype 2 agonist. A disclosed compound represented by the general formula (I): wherein all symbols have the same definitions as described in the specification; a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing is a low-molecular compound having strong somatostatin receptor subtype 2 agonistic activity, and thus can be administered in a simple manner, has high stability and has low toxicity. Therefore, the present compound is useful for prophylaxis and/or therapy of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.Type: ApplicationFiled: September 29, 2014Publication date: October 27, 2016Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akiharu ISHIDA, Takeshi MATSUSHITA, Tetsuya SEKIGUCHI, Yasuyuki OKABE, Tatsuya KOMAGATA, Takuya NISHIO
-
Publication number: 20160213660Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.Type: ApplicationFiled: April 4, 2016Publication date: July 28, 2016Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi NAGANAWA, Kensuke KUSUMI, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Akito KAKUUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Shigeyuki NONAKA
-
Patent number: 9340499Abstract: The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.Type: GrantFiled: January 8, 2015Date of Patent: May 17, 2016Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
-
Publication number: 20160039757Abstract: An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.Type: ApplicationFiled: March 25, 2014Publication date: February 11, 2016Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Kensuke KUSUMI, Atsushi NAGANAWA, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Yasuko YAMAMOTO